Related Experiment Video

Updated: Jun 13, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

Mucosally restricted antigens as novel immunological targets for antitumor therapy

Adam E Snook1, Benjamin J Stafford, Laurence C Eisenlohr

  • 1Thomas Jefferson University, Department of Pharmacology and Experimental Therapeutics, Philadelphia, PA, USA. adam.snook@jefferson.edu

Biomarkers in Medicine
|May 19, 2010
PubMed

Insights

Colorectal cancer immunotherapy shows promise by targeting novel cancer mucosa antigens, like guanylyl cyclase C, to combat metastatic disease. This approach exploits immune system compartmentalization for better therapeutic outcomes.

Area of Science:

  • Oncology
  • Immunology
  • Biomarker Discovery

Background:

  • Colorectal cancer is a leading cause of cancer mortality globally.
  • Current treatments, including surgery, have limited efficacy against metastatic disease, with ~50% of patients developing metastases.
  • Existing immunotherapies face challenges due to a lack of specific tumor-associated antigens.

Purpose of the Study:

  • To explore the potential of targeting cancer mucosa antigens for colorectal cancer immunotherapy.
  • To investigate the use of immune system compartmentalization to generate therapeutic responses against metastatic colorectal tumors.
  • To validate guanylyl cyclase C as a novel, intestinal mucosa-specific target for colorectal cancer immunotherapy.

Main Methods:

  • Review of colorectal cancer immunity and immune compartmentalization principles.
  • Discussion of preliminary results from targeting guanylyl cyclase C in mouse models of colorectal cancer.
  • Exploration of the paradigm shift towards using cancer mucosa antigens in cancer immunotherapy.

Main Results:

  • Identified a novel class of biomarkers, termed cancer mucosa antigens, with potential for colorectal cancer immunotherapy.
  • Guanylyl cyclase C demonstrated suitability as an intestinal mucosa-specific target.
  • Preliminary data in mouse models suggest the feasibility of targeting guanylyl cyclase C.

Conclusions:

  • Cancer mucosa antigens represent a promising new avenue for colorectal cancer immunotherapy.
  • Targeting guanylyl cyclase C offers a potential strategy to overcome limitations of current treatments.
  • Exploiting immune compartmentalization with specific biomarkers could significantly improve therapeutic efficacy for colorectal cancer.

More Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Antigens Involved in Adaptive Immunity01:26

Antigens Involved in Adaptive Immunity

An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...